Crizotinib in MET-deregulated or ROS1-rearranged pretreated non–small cell lung cancer (METROS): A phase II, prospective, multicenter, two-arms trial

L. Landi, R. Chiari, M. Tiseo, F. D'Inca, C. Dazzi, A. Chella, A. Delmonte, L. Bonanno, D. Giannarelli, D.L. Cortinovis, F. de Marinis, G. Borra, A. Morabito, C. Gridelli, D. Galetta, F. Barbieri, F. Grossi, E. Capelletto, G. Minuti, F. MazzoniC. Verusio, E. Bria, G. Al, R. Bruno, A. Proietti, G. Fontanini, L. Crino, F. Cappuzzo

Research output: Contribution to journalArticle

Cite this

Landi, L., Chiari, R., Tiseo, M., D'Inca, F., Dazzi, C., Chella, A., Delmonte, A., Bonanno, L., Giannarelli, D., Cortinovis, D. L., de Marinis, F., Borra, G., Morabito, A., Gridelli, C., Galetta, D., Barbieri, F., Grossi, F., Capelletto, E., Minuti, G., ... Cappuzzo, F. (2019). Crizotinib in MET-deregulated or ROS1-rearranged pretreated non–small cell lung cancer (METROS): A phase II, prospective, multicenter, two-arms trial. Clinical Cancer Research, 25(24), 7312-7319. https://doi.org/10.1158/1078-0432.CCR-19-0994